Inhibition of CDK4 and 6 currently constitutes the standard of care for recurrent ER positive breast cancers in combination with endocrine therapies, though progression under such treatment may develop through (e.g.)activation of Tyr kinase receptors44. The gene discussed is CDK4; the disease is breast carcinoma.